CAPRICOR THERAPEUTICS, INC.·4

Feb 23, 9:00 AM ET

Manzo Louis 4

4 · CAPRICOR THERAPEUTICS, INC. · Filed Feb 23, 2023

Insider Transaction Report

Form 4
Period: 2023-02-21
Manzo Louis
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2023-02-21$1.39/sh+1,401$1,94762,599 total
  • Disposition to Issuer

    Common Stock

    2023-02-21$4.31/sh452$1,94862,147 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-02-211,4010 total
    Exercise: $1.39Exp: 2023-04-22Common Stock (1,401 underlying)
Footnotes (3)
  • [F1]Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on February 21, 2023 of $4.31. The options would otherwise expire on February 22, 2023, pursuant to their terms.
  • [F2]This option was granted on February 22, 2013 and was previously reported as covering 14,015 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
  • [F3]25% of the shares vested immediately, with the remainder vesting monthly over 36 months commencing May 1, 2013.

Documents

1 file
  • 4
    form4-02232023_090208.xmlPrimary